Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

background

Cancer treatment involves the participation of multiple medical specialties and, as our knowledge of the disease increases, this fact becomes even more apparent [1]. The degree of multidisciplinarity is determined by several factors, which include the severity and type of disease, the increasing diversity in the available pharmacological and non-pharmacological therapies, and the range of specialists involved in cancer therapy, such as medical oncologists, radiotherapists, gynecologists, gastroenterologists, urologists, surgeons, and pneumologists, among others. Across Europe, the situation of cancer care can be variable due to the diversity of health systems, differences in drug reimbursement, and the degree of establishment of Medical Oncology as a medical specialty in the European Union states [2].

Within this multidisciplinary approach, each of the specialties involved in cancer treatment has a specific role, and according to an international panel of experts, the medical oncologist is the physician who plans global cancer treatment, administers systemic anticancer therapies to the patient, and takes care of the general well-being of the patient [3].

the use of orally administered anticancer drugs

Oral anticancer drugs have been available since the early days of cancer treatment, although their use had been limited due to, among other reasons, their sometimes unpredictable oral bioavailability, and i.v. agents were preferred. This approach has changed in recent years as a number of cytotoxic drugs such as capecitabine, vinorelbine, or topotecan have become available as oral agents for the treatment of a large variety of tumors like colon, breast, gastric, ovarian, or lung cancer (Table 1). More importantly, the introduction of therapies directed against specific molecular targets has steered the use of oral drugs into the heart of daily oncology practice. Indeed, almost half of the targeted molecules approved for the treatment of cancer in the European Union since the year 2000 are exclusively available as oral formulation (Table 1) [5-8]. Furthermore, the proportion of oral antitumor agents being developed today far exceeds three-quarters of all the cancer therapies that are currently under development [9]. Additionally, some oral anticancer treatments are perceived by most patients as a valuable way to cope with their diseases without many side-effects, visits to the clinic, or venipunctures [10]. Hence, it is hardly surprising that some cancer patients may prefer the use of oral to i.v. chemotherapy, even at the expense of sacrificing part of the clinical efficacy [11, 12].

the issue

Along with the growing numbers of oral drugs available for the treatment of cancer, we have observed with great concern that some of these drugs have been moving out of the use by the oncology experts and into that of other physicians that are less familiar with comprehensive cancer treatment. In Spain, we estimate that this practice represents, depending on a particular oral anticancer drug, from ~5% to >20%. This is very likely to eventually pose a risk to cancer patients. The use of oral cancer treatments by physicians unfamiliar with routine oncology practice is worrisome because it compromises the excellence of oncological practice and may result in a deterioration of the medical care received by cancer patients.

Therefore, the Spanish Society of Medical Oncology (SEOM) wishes to state its point of view on this subject to the medical community, with the objective to open a debate, as has been done in the past with other oncology-related subjects as the off-label use of drugs in oncology or the cancer care in the elderly population [13, 14].

the position statement

The SEOM was founded in 1980, 2 years after the specialty of Medical Oncology was established in Spain [15]. In Spain, the Ministries of Health and Education determine the requirements, the duration, and, above all, the contents of the training programs for each of the medical and surgical specialties, including Medical Oncology [16]. The Spanish training program of Medical Oncology includes all cancer-related issues, namely the molecular biology, epidemiology, diagnostic procedures, the anticancer drugs, and the methodology to be followed in the various types of clinical trials based on the guidelines for Good Clinical Practice. Additionally, Medical Oncology is the only specialty in Spain that covers specifically the pharmacological treatment of cancer using drugs administered i.v., orally, or by any other route. The Spanish Medical Oncology training program has much in common with standards setup jointly by the European Society for Medical Oncology and the American Society of Clinical Oncology [3].

In our opinion, Medical Oncology specialists are presently the best-trained professionals to plan and administer systemic anticancer therapies throughout all European countries in which this medical specialty exits [3]. In addition to Medical
Oncology specialists, there are some physicians in Europe who may be empowered to treat cancer patients. Thus, in some European countries, there are superspecialists within gynecology, gastroenterology, urology, or pneumology that may have the necessary training to qualify them to treat with drugs certain cancer types, although not all. Also, we must take into account those individual cases of physicians who, although not having formal oncology training, have acquired supervised or unsupervised experience during years of practice.

Why are professionals who are not fully trained or experienced in the pharmacotherapy of cancer prescribing oral antineoplastics? There are several reasons explaining this, among which is the belief that oral anticancer drugs have a lower toxicity, and hence their delivery does not require specific skills or knowledge, or that the administration outside of a day hospital facilitates the outpatient prescription of these agents. Furthermore, the possibility of using novel molecular-targeted drugs may be tempting from a professional point of view because of using ‘modern’ drugs. This is especially true in the field of cancer therapy, which has led the pharmacological molecular revolution that we are witnessing nowadays. In addition, there is a clear marketing pressure applied by pharmaceutical companies to non-oncology specialists for the use of their latest generation drugs.

Several solid reasons support our warning that the administration of oral anticancer drugs outside the scope of trained oncologists should be considered unsuitable and potentially dangerous.

- It is not true that oral anticancer drugs are less toxic. Although the toxicity profiles of the newer molecularly targeted drugs are less focused on blood cells than those of the traditional chemotherapeutics, they are not, in any sense, insignificant (Table 2). This class of drugs retains the potential for severe and possibly lethal adverse events, whose diagnosis and treatment cannot be properly handled by untrained physicians who do not work in a multidisciplinary environment. Thus, any antitumor therapy, whether administered orally or i.v., whether cytostatic or molecularly targeted, requires safe and careful handling by an experienced specialist and preferably one who has been formally trained in their use.

- The evaluation of the clinical response according to universally accepted criteria is key to anticancer drug administration [17, 18]. Only the training programs in Medical Oncology specifically include this expertise [3, 5]. Furthermore, in some malignancies, such as gastrointestinal stromal tumors, the response criteria used are specifically tailored for a single disease [19]. Physicians, if unfamiliar with the subtleties of oncology practice, may keep administering a drug as long as the patient seems to be tolerating it well, hence confusing ‘clinical appearance’ with ‘clinical response’. In oncology, the term ‘clinical benefit’ means objective response or disease stability in the absence of limiting toxicity [20]. This concept implies carrying out regular and objective evaluations of the tumor’s response to therapy.

- A physician untrained in cancer therapy who decides to prescribe an oral anticancer drug may often administer it as monotherapy because he may feel uncomfortable using the whole range of anticancer agents. Based on wider experience, a medical oncologist will choose the best treatment, either as monotherapy or in combination with other oral or i.v. antitumor drugs, depending on the patient’s situation and the existence of published evidence which supports their use.

- Often, an untrained physician will be familiarized with the use of one oral agent only. For this reason, treatment options offered to a patient may be in these cases just two: either to be treated with that single drug or to be not treated at all. At the heart of a multidisciplinary team that includes a medical oncologist, many treatment options are available. Oral therapy is usually one among several possibilities. The alternatives range from various types of surgeries, radiotherapy, combinations of a variety of chemotherapeutics and biological agents, participation in clinical trials, or referral to an oncology palliative care team. In this era of individualized medicine, cancer treatment in inexperienced hands implies a clear limitation in the chances of tailoring treatments according to the individualized needs of a patient.

- Oncology teams have acquired a particular medical culture founded upon the use of protocols. Not only are anticancer

| Oral drug     | EMEA approval date | Indications                                                                 |
|---------------|--------------------|-----------------------------------------------------------------------------|
| Capecitabine  | February 2001      | Colorectal cancer, gastric cancer, breast cancer                             |
| Dasatinib     | November 2006      | Chronic myeloid leukemia, acute lymphoblastic leukemia, lymphoid blast chronic myeloid leukemia |
| Erlotinib     | September 2005     | Non-small-cell lung cancer, pancreatic cancer                               |
| Fludarabine   | July 2002          | B-cell chronic lymphocytic leukemia                                          |
| Imatinib      | November 2001      | Chronic myeloid leukemia, acute lymphoblastic leukemia, chronic eosinophilic leukemia, malignant gastrointestinal stromal tumors, dermatofibrosarcoma protuberans |
| Lapatinib     | June 2008          | Breast cancer                                                               |
| Nilotinib     | November 2007      | Chronic myelogenous leukemia                                                 |
| Sorafenib     | July 2006          | Hepatocellular carcinoma, renal cell carcinoma                              |
| Sunitinib     | July 2006          | Malignant gastrointestinal stromal tumor, renal cell carcinoma               |
| Thalidomide   | April 2008         | Multiple myeloma                                                            |
| Vinorelbine   | April 2004         | Breast cancer, lung cancer                                                   |
| Topotecan     | April 2008         | Ovarian cancer, lung cancer, cervix cancer                                   |

*i.v. anticancer drugs approved by the EMEA since 2000: alemtuzumab, bevacizumab, bortezomib, cetuximab, liposomal doxorubicin, liposomal paclitaxel, panitumumab, pemetrexed, temsirolimus, and trastuzumab.
Table 2. Main toxic effects of oral anticancer drugs [4]

| Oral drug  | Relevant toxic effects                                                                 |
|------------|----------------------------------------------------------------------------------------|
| Capecitabine | Diarrhea, vomiting, stomatitis, hand–foot syndrome, pancytopenia, electrolyte disorders, cholestasis |
| Dasatinib  | Pleural effusion, dyspnea, diarrhea, vomiting, skin rash, hemorrhage                     |
| Erlotinib  | Rash, diarrhea, electrolyte disorders, renal failure                                     |
| Fludarabine| Pancytopenia, severe infections, vomiting, diarrhea, neuropathy, visual disturbances     |
| Imatinib   | Pancytopenia, vomiting, diarrhea, edema, rash, pleural and pericardial effusion          |
| Lapatinib  | Diarrhea, vomiting, rash, stomatitis, hand–foot syndrome                                |
| Nilotinib  | Pancytopenia, diarrhea, rash, pruritus, hyperlipidemia                                  |
| Sorafenib  | Lymphopenia, hypophosphatemia, hemorrhage, hypertension, diarrhea, vomiting, rash, hand–foot syndrome, erythema, pruritus, pancreatitis |
| Sunitinib  | Pancytopenia, hypertension, diarrhea, stomatitis, vomiting, skin and hair discoloration, hand–foot syndrome, rash, epistaxis, glossodynia, decreased ejection fraction, hypothyroidism |
| Thalidomide| Pancytopenia, peripheral neuropathy, tremor, paresthesia, somnolence, peripheral edema  |
| Vinorelbine| Pancytopenia, neuropathy, vomiting, diarrhea, stomatitis, esophagitis                    |
| Topotecan  | Pancytopenia, diarrhea, mucositis, vomiting                                              |

In everyday oncology practice, medical therapy and clinical research are so closely linked that it is almost unthinkable to consider them apart. The inclusion of patients in large cooperative clinical trials not only constitutes the best treatment option for many patients but is also a key element in the development of cancer therapy. The sponsors of clinical trials are often either large research cooperative groups or multinational pharmaceutical companies. In these studies, only those professionals who are integrated into solid multidisciplinary teams; who have the infrastructure, the knowledge, the experience, and the motivation necessary to achieve a high recruitment volume; and who demonstrate an impeccable adherence to the complex research protocols are invited to participate. For patients, being treated outside the oncological expertise may result in missing the opportunity to be included in a clinical trial. For clinical research itself, this may translate into a decrease in the number of patients recruited in clinical trials and in a difficulty in controlling selection bias.

Conclusions

SEOM has observed that untrained physicians outside the Medical Oncology specialty field are prescribing oral anticancer drugs to patients with cancer. This practice is sometimes based on false assumptions about the easiness of administration or the toxic effects profile of the newer oral anticancer drugs. Cancer therapy implies a global responsibility that goes beyond the prescription of a single drug: it is a commitment that encompasses many aspects of the medical care that is offered to a patient and reaches the society as a whole. The responsibility of safe and effective delivery can only be guaranteed within the heart of multidisciplinary teams who have undergone thorough training in all aspects of comprehensive cancer care and who are governed by strict protocols, have wide therapeutic experience, and are either led or coordinated by medical oncologists. We believe that the prescription of anticancer drugs by physicians who are not oncology experts may compromise the current standards of safety and efficacy in the medical care offered to cancer patients and the high quality of cancer research.

SEOM wishes to alert our European Medical Oncology colleagues, the European national health care providers, the international oncology community as a whole, and the general public about this situation and to encourage awareness among health care providers. SEOM believes that regulatory measures to deal with this problem should be undertaken both locally and nationally.

R. Colomer1*, E. Alba3, A. González-Martin1, L. Paz-Ares3, M. Martín4, A. Llombart5, A. Rodríguez Lescure6, J. Salvador7, J. Albanell8, D. Islà8, M. Lomas10, C. A. Rodríguez11, J. Trigo5, J. R. Germa12, J. Bellmunt8, J. Tabernero13, R. Rosell14, E. Aranda15, R. Cubedo16 & J. Baselga13 On behalf of the Spanish Society of Medical Oncology

1Centro Oncológico MD Anderson España, Madrid, 2Hospital Virgen de la Victoria, Málaga, 3Hospital Virgen del Roció, Sevilla, 4Hospital Gregorio Marañón, Madrid, 5Hospital Arnau de Vilanova, Lleida, 6Hospital General Universitario de Elche, Elche, 7Hospital Nuestra Señora de Valme, Sevilla, 8Hospital del Mar-IMIM, Barcelona, 9Hospital Clínico Universitario Lozano Blesa, Zaragoza, 10Complejo Hospitalario de Jaén, Jaén, 11Hospital Universitario de Salamanca, Salamanca, 12Hospital Duran i Reynals, Barcelona, 13Hospital Universitario Vall d'Hebron, Barcelona, 14Institut Català d’Oncologia-Hospital Germans Trias i Pujol, Barcelona, 15Hospital Reina Sofía, Córdoba, 16Hospital Puerta de Hierro, Madrid, Spain

(*E-mail: rcolomer@seom.org)
acknowledgements

Editorial assistance for the development of the manuscript was provided by Beatriz Gil-Alberdi from HealthCo (Madrid, Spain). The members of the SEOM Executive Committee 2007–2009 are RC, EA, AL, MM, ARL, JS, JA, AG-M, DI, ML, CAR, and JMT. LP-A, RR, EA, JT, MM, AG-M, JRG, JB, and JMT represent the Spanish cancer research groups (a full list can be obtained at http://www.seom.org/seomcms/index.php?option=com_content&task=section&id=16&Itemid=272).

disclosures

The SEOM acknowledges the support for this project of unrestricted grants from Pfizer, Spain; Pierre Fabre Medicament, Spain; GlaxoSmithKline, Spain; Bayer HealthCare, Spain; and Novartis Farmacéutica, Spain.

references

1. Bajetta E, Gevorgyan A, Mellstedt H. National integration of European standards. Ann Oncol 2007; 18: 969–970.
2. ESMO. Medical Oncology Status in Europe Survey (MOSES). http://www.esmo.org/policy/status-of-medical-oncology-in-europe.html.
3. Hansen HH, Bajorin DF, Muss HB et al. Recommendations for a global core curriculum in Medical Oncology. Ann Oncol 2004; 15: 1603–1612.
4. EMEA. EPARs for authorised medicinal products for human use. http://www.emea.europa.eu/hms/human/epar/a.htm.
5. Gralow J, Ozols RF, Bajorin DF et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2008; 26: 313–325.
6. Herbst RS, Bajorin DF, Bleiberg H et al. Clinical cancer advances 2005: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2006; 24: 190–205.
7. Ozols RF, Herbst RS, Colson YL et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2007; 25: 146–162.
8. Winer E, Gralow J, Diller L et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2009; 27: 812–826.
9. Medicines in Development for Cancer. http://www.phrma.org/medicines_in_development_for_cancer/.
10. Catania C, Didier F, Leon ME et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005; 92: 265–272.
11. Jensen LH, Osterlund K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer 2008; 62: 85–91.
12. Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–115.
13. Position paper by the UKCCCR elderly cancer patients in clinical trials working group. Br J Cancer 2000; 82: 1–3.
14. Casali PG. The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol 2007; 18: 1923–1925.
15. Estatutos de la Sociedad Española de Oncología Médica (SEOM). http://www.seom.org/seomcms/images/stories/recursos/conoceoseom/associarse/2006/estatutos.pdf.
16. Medical Oncology Training Program. 19086-ORDEN SCO/3370/2006, de 9 de octubre, por la que se aprueba y publica el programa formativo de la especialidad de Oncología Médica. Bol Of Estado 2006; 262: 38122–38129. http://www.msc.es/profesionales/formacion/guiaFormacion.htm.
17. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228–247.
18. Therasse P, Le Cesne A, Van Glabbeke M et al. RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer 2005; 41: 1426–1430.
19. Benjamen RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760–1764.
20. Dhani N, Tu D, Sargent DJ et al. Alternate endpoints for screening phase II studies. Clin Cancer Res 2009.